Imagine millions of families grappling with the sudden storm of acute agitation—a terrifying surge of confusion and unrest that can strike during bipolar disorder or schizophrenia episodes, turning everyday moments into crises. This isn't just a statistic; it's a real challenge that leaves patients, caregivers, and loved ones desperate for better solutions. But here's where it gets intriguing: what if the power to calm these storms could shift from busy emergency rooms to the comfort of home? Join us as we explore this groundbreaking idea in our rewritten take on an exciting upcoming event.
Renowned journalist Anjalee Khemlani, celebrated for her insightful coverage on Yahoo Finance and NJBIZ, is set to moderate a virtual discussion featuring top-tier medical professionals. This engaging one-hour session, sponsored by BioXcel Therapeutics, kicks off at 10 a.m. EST on Monday, December 8. It's your chance to tune in and learn about cutting-edge advancements in managing acute agitation tied to neuropsychiatric issues like bipolar disorder and schizophrenia.
To put it simply for those new to this topic, acute agitation refers to intense episodes of restlessness, irritability, or emotional turmoil that can flare up unexpectedly, often requiring quick intervention to prevent harm or escalation. Picture a scenario where someone in the midst of a manic episode feels overwhelmed and unsafe—traditional care might involve a trip to a hospital or clinic, but emerging options are paving the way for safer, more convenient alternatives right in one's living space. And this is the part most people miss: with an astounding 57 to 77 million such incidents happening at home across the United States each year, the need for innovative, patient-friendly treatments has never been clearer. This roundtable isn't just talk; it's a peek into how care models are evolving, potentially transforming how we handle these situations outside of emergency departments, psychiatric wards, or nursing facilities.
The conversation will spotlight the benefits and opportunities of self-administered treatments that patients could manage from home—think user-friendly medications or tools designed for safety and effectiveness. But here's where it gets controversial: while the idea of empowering patients sounds empowering, is there a risk that home-based care might overlook the need for professional oversight, potentially leading to misuse or delayed professional help? It's a debate worth having, as it touches on balancing independence with safety in mental health.
Leading the discussion are three esteemed experts:
- Dr. Leslie Citrome, M.D., M.P.H., a Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College, known for his expertise in treatment innovations.
- Dr. Marc A. Milano, M.D., FACEP, who chairs the Department of Emergency Medicine at Newark Beth Israel Medical Center and Children’s Hospital of New Jersey, bringing a frontline perspective on urgent care.
- Dr. Leon Ravin, M.D., a psychiatrist and the Statewide Psychiatric Medical Director for the Division of Public and Behavioral Health in Nevada, offering insights into statewide mental health strategies.
Participants can submit questions through a live written Q&A feature, making it interactive and inclusive. Plus, for those who can't attend, a full recording will be available on the BioXcel Therapeutics website shortly after the event.
Sign up now via this link: https://event.webcasts.com/starthere.jsp?ei=1744467&tp_key=14d071615e to secure your spot and dive into these vital discussions.
A bit about the sponsor: BioXcel Therapeutics, Inc. (traded on Nasdaq as BTAI) is a forward-thinking biopharmaceutical firm harnessing artificial intelligence to create revolutionary drugs in neuroscience. Their subsidiary, OnkosXcel Therapeutics, focuses on immuno-oncology treatments, while the company's core strategy involves "drug re-innovation"—revitalizing existing approved medications or candidates with big data and advanced machine learning to uncover new uses. For instance, they might repurpose a familiar drug for an unexpected application, like adapting something originally for another condition to better suit neuropsychiatric needs, all while prioritizing safety and efficacy.
This event, announced from New Haven, Connecticut, on December 3, 2025, highlights why staying informed is key. As we wrap up, let's ponder: Do you think self-administered treatments for acute agitation could truly revolutionize care, or might they introduce new risks that outweigh the benefits? Share your thoughts in the comments—do you agree this shifts power to patients, or does it raise concerns about accountability? We'd love to hear your take and spark a conversation!
For more details or to get in touch:
Corporate/Investors
Russo Partners
Nic Johnson
nic.johnson@russopartnersllc.com
1.303.482.6405
Media
Russo Partners
David Schull
david.schull@russopartnersllc.com
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
